1 / 37

Osteoporosis – Controversies and Promising Treatment Options

Osteoporosis – Controversies and Promising Treatment Options. Keith R. Holden, M.D. Ponte Vedra Beach, FL www.Dr-Holden.com. Osteoporosis Controversies. Guidelines for prevention and tx vary Bone quality versus bone quantity Same BMD can have different fx risk (age)

sona
Download Presentation

Osteoporosis – Controversies and Promising Treatment Options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Osteoporosis – Controversies and Promising Treatment Options Keith R. Holden, M.D. Ponte Vedra Beach, FL www.Dr-Holden.com

  2. Osteoporosis Controversies • Guidelines for prevention and tx vary • Bone quality versus bone quantity • Same BMD can have different fx risk (age) • Cumbersome dosing requirements • Drug side effects

  3. Bisphosphonate Side Effects • Esophagitis • Esophageal stricture • Esophageal cancer • Osteonecrosis of jaw • Atypical Femur Fracture

  4. Atypical Femur Fracture (AFF) • Bisphosphonates ↓ osteoclast fxn & induce osteoclast apoptosis • Suppress bone resorption = hard, brittle bone • Path: ↓ bone heterogeneity = ↓ bone quality • Complete lack of TCN labeling = severe ↓ bone formation • Stress injury-like cortical hypertrophy in other femur with unilateral AFF

  5. Limitations of BMD Tests (DEXA) • ↑ BMD does not always = ↑ bone strength • T-score not consistent predictor of osteoporosis outside of elderly postmenopausal white♀ • Other populations, Z score may be better predictor of low bone density

  6. Fracture Risk Tool • www.shef.ac.uk/FRAX/tool.jsp • FRAX estimates 10-yr. fx risk based on BMD femoral neck + osteo risk factors

  7. Bone Quality vs Bone Quantity • Bone quality = bone strength (cortical bone structure/quality of collagen) + rate of remodeling • Bone densitometry measures BMD (quantity), helps assess fx risk, aids in dx of osteo, but does NOT measure bone quality

  8. Living Matrix of Bone • Healthy bone requires a balance of: • Bone building by osteoblasts • Resorption by osteoclasts

  9. Osteoid Matrix of Bone • 90% collagen (majority Type 1) • Osteoclast degradation & osteoblast synthesis create circulating peptides of Type 1 collagen • Type I collagen is cross-linked by deoxypyridinoline (DPD) • DPD provides rigidity and strength (quality) to bone

  10. Usefulness of Bone Biomarkers • Reflects bone remodeling yrs. before BMD ∆ • ↑ T score + ↑ biomarker → fx risk (odds 4.1) • Allow tracking of response to therapy • May improve adherence to therapy

  11. Urinary Deoxypyridinoline (uDPD) • Cross-link Type IC (relatively selective) • Measure of bone resorption - ↑ urine level > bone loss • Unaffected by diet • Easy to measure spot AM urine • Recheck within 30-90 days after initiating therapy • Covered by Medicare

  12. Effective Supplements for Bone • Calcium • Vitamin D • Magnesium • Boron • Strontium ranelate • Ipriflavone • Vitamin K • Choline stabilized orthosilicic acid (ch-OSA)

  13. Choline stabilized orthosilicic acid • Ch-OSA = bioavailable silicon • RDBPC trial: added to calcium and D3 showing improved bone biomarkers and BMD ↑ 2% • RDBPC trial: ↑ tensile strength of hair • RDBPC trial: + effects of skin surface changes, mechanical properties, ↓ brittleness hair/nails

  14. Biophysics and Bone Health • Pulsed Electromagnetic Field (PEMF) therapy has shown promise in clinical trials for tx and prevention of osteoporosis • Mediates process via cell signaling proteins – growth factors, cytokines, and prostaglandins

  15. PEMF Clinical Trials and Osteoporosis

  16. PEMF Improves BMD • PEMF 72Hz 10 hrs daily for 12 wks to radius of “osteoporosis prone” ♀ • BMD showed sig. inc. in exposed areas 36 wks • Similar but weaker response in non-treated arm (Tabrah, et. al., 1990)

  17. PEMF Suppresses Bone Loss in DOP • Evaluated rats with surgically induced DOP • After 8 wks, PEMF sig. ↑BMD, ↑ TGF-beta 1, ↓IL-6 in proximal femur • Conclusion: PEMF efficiently suppresses bone loss in DOP via local factors (Shen, et al., 2010)

  18. PEMF Chronotherapy in (OVX) rats • Evaluated CR with PEMF in ovariectomy-induced osteoporosis in rats • 12 weeks, (OVX-DPEMF) group had better prevention against OVX-induced bone loss • ↑BMD, ↑osteoblast activity, ↑ trabecular health markers; ↓bone markers of resorption (uDPD) (Jing, et. al., 2010)

  19. PEMF ↓ DM Induced Bone Loss • Rats with streptozotocin-induced DM bone loss • PEMF daily 8 hrs x 8 wks • PEMF improved biomechanical bone quality DM bone • PEMF partially reversed DM-induced bone deterioration • Conclusion: PEMF might become an additive method for inhibiting DM osteoporosis (Jing, et al., 2011)

  20. PEMF Affects Osteoblasts • Study on in-vitro osteoblastic cell culture • PEMF ↑osteoblastic growth, ↑ TGF-beta 1 • PEMF ↓ prostaglandin E2 • Conclusion: Study sheds light on mechanism of action of PEMF in non-union fx & prevention of osteoporosis (Li, et al., 2007)

  21. PEMF Prevents Osteoporosis • Studied rats subjected to bil ovariectomy • PEMF augmented/restored trabecular bone mass/architecture in PEMF groups • PEMF attenuated higher serum PGE(2) of OVX rats and restored levels to that of controls • Conclusion: PEMF may be useful in prevention of osteoporosis resulting from ovariectomy (Chang, et al., 2003)

  22. PEMF modulates osteoblast cells • PTH used to tx osteoporosis; Insulin & IGF-1 anabolic roles in osteogenesis • Cell signaling proteins IRS-1, S6 RSK, & eNOS were phosphorylated by PTH, Insulin, & PEMF to the same extent in osteoblast-like cells • Conclusion: Anabolic affects of PEMF may be mediated through these proteins (Schnoke, et. al., 2007)

  23. Summary PEMF Physiologic Effects • ↑ BMD • ↑ TGF-beta 1 • ↓ IL-6 • ↓ PGE(2) • ↑ osteoblast growth • Phosphorylation of IRS-1, S6 RSK, eNOS

  24. Clinical Approach to Osteoporosis

  25. Use Food as Medicine • Alkalinizing plant based diet • Address food sensitivities • Mineral rich foods

  26. Optimize Gut Health – 5Rs • Remove • Replace • Reinnoculate • Repair • Rebalance

  27. Address Regulatory Blockades • Foci of interference (ANS) • Stress • Inflammation • Toxins • Allergy • Infection (occult, dysbiosis, dental) • Heavy metals

  28. Supporting Factors • Resistance training • Nutritional supplementation • Hormonal balance • PEMF

  29. Osteoporosis Case Studies

  30. Case Study #1 66 y.o ♀ with osteoporosis (T-score -3.1) • Baseline: mostly plant based diet, resistance training, Ca, Mg, and D • (1/27/11) uDPD 9.7 nM/mM Cr (NL < 6.5) • Weekly 1 hr PEMF sessions x 2 mos • (3/16/11) uDPD 4.5 (53% drop!) • Maintenance: Monthly 1 hr PEMF • (7/21/11) uDPD 5.5 • (10/24/11) uDPD 4.5

  31. Case Study #1 Urine DPD

  32. Case Study #2 63 y.o. ♀ osteoporosis (‘09 T-score LS -3.9; ‘11 T-score LS -4.1) • Hx FMG, CFS, IBS, MCS & hx multiple fxs • Baseline: BHRT, Ca, Mg, D • Added ch-OSA + tx gut dysbiosis • Started PEMF (3/26/11) monthly; (7/26/11) inc. freq. to weekly; (9/12/11) 2-3 X week • (4/13/11) uDPD 9.7; (10/4/11) uDPD 5.0 (48.45% drop!)

  33. Case Study #2

  34. Case Study #2

  35. Case Study #2

  36. Case Study #2

  37. Contact Information Keith R. Holden, M.D. 822 A1A North, Suite 310 Ponte Vedra Beach, FL 32082 (904) 473-4954 krholden@gmail.com www.Dr-Holden.com

More Related